NCT01647971 2022-11-21Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaTG Therapeutics, Inc.Phase 1/2 Completed39 enrolled
NCT01744912 2022-05-11Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid MalignanciesTG Therapeutics, Inc.Phase 1 Terminated10 enrolled